Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
Immune checkpoint inhibitors, including those targeting CTLA-4/B7 and PD-1/PD-L1 inhibitory pathways, are now available for clinical use on cancer patients. Other interesting checkpoint inhibitors are currently under the development. CD47 is a protein broadly expressed on the surface of normal cells...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2018-08-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0217.htm |
| _version_ | 1818516246781493248 |
|---|---|
| author | ZHA Li YU Jiaojiao XU Bin |
| author_facet | ZHA Li YU Jiaojiao XU Bin |
| author_sort | ZHA Li |
| collection | DOAJ |
| description | Immune checkpoint inhibitors, including those targeting CTLA-4/B7 and PD-1/PD-L1 inhibitory pathways, are now available for clinical use on cancer patients. Other interesting checkpoint inhibitors are currently under the development. CD47 is a protein broadly expressed on the surface of normal cells and often overexpressed in cancer cells, and its receptor is the myeloid inhibitory immunoreceptor SIRPα. Blocking CD47-SIRPα interactions has been shown to promote the destruction of cancer cells by phagocytes, including macrophages and neutrophils. Furthermore, there is growing evidence that targeting CD47-SIRPα axis may also promote antigen-presenting cell function and thereby stimulate T cell-mediated anti-cancer immunity. In summary, with the clinical studies about CD47-SIRPα checkpoint inhibitors expected within the coming years, this is an exciting and rapidly developing field. |
| first_indexed | 2024-12-11T00:39:32Z |
| format | Article |
| id | doaj.art-7b108456ae5141e19dfefec632a42ced |
| institution | Directory Open Access Journal |
| issn | 1000-8578 1000-8578 |
| language | zho |
| last_indexed | 2024-12-11T00:39:32Z |
| publishDate | 2018-08-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-7b108456ae5141e19dfefec632a42ced2022-12-22T01:26:59ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85781000-85782018-08-0145860460810.3971/j.issn.1000-8578.2018.18.02178578.2018.18.0217Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in CancerZHA Li0YU Jiaojiao1XU Bin2Department of Ultrasound, Hubei Cancer Hospital, Wuhan 430079, ChinaDepartment of Ultrasound, Hubei Cancer Hospital, Wuhan 430079, ChinaDepartment of Oncology I, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaImmune checkpoint inhibitors, including those targeting CTLA-4/B7 and PD-1/PD-L1 inhibitory pathways, are now available for clinical use on cancer patients. Other interesting checkpoint inhibitors are currently under the development. CD47 is a protein broadly expressed on the surface of normal cells and often overexpressed in cancer cells, and its receptor is the myeloid inhibitory immunoreceptor SIRPα. Blocking CD47-SIRPα interactions has been shown to promote the destruction of cancer cells by phagocytes, including macrophages and neutrophils. Furthermore, there is growing evidence that targeting CD47-SIRPα axis may also promote antigen-presenting cell function and thereby stimulate T cell-mediated anti-cancer immunity. In summary, with the clinical studies about CD47-SIRPα checkpoint inhibitors expected within the coming years, this is an exciting and rapidly developing field.http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0217.htmcancercd47sirpαimmune checkpointimmunotherapy |
| spellingShingle | ZHA Li YU Jiaojiao XU Bin Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer Zhongliu Fangzhi Yanjiu cancer cd47 sirpα immune checkpoint immunotherapy |
| title | Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer |
| title_full | Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer |
| title_fullStr | Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer |
| title_full_unstemmed | Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer |
| title_short | Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer |
| title_sort | research progress of cd47 sirpα signaling axis as an innate immune checkpoint in cancer |
| topic | cancer cd47 sirpα immune checkpoint immunotherapy |
| url | http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0217.htm |
| work_keys_str_mv | AT zhali researchprogressofcd47sirpasignalingaxisasaninnateimmunecheckpointincancer AT yujiaojiao researchprogressofcd47sirpasignalingaxisasaninnateimmunecheckpointincancer AT xubin researchprogressofcd47sirpasignalingaxisasaninnateimmunecheckpointincancer |